Spots Global Cancer Trial Database for Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer
Official Title: Clinical First-in-human Single-dose Escalation Study Evaluating the Safety and Tolerability of Claudiximab (iMAB-362) in Hospitalized Patients With Advanced Gastroesophageal Cancer. A Multi-center, Phase I, Open-label, i.v. Infusion Study
Study ID: NCT00909025
Conditions
Interventions
Study Description
Brief Summary: Claudiximab is a monoclonal antibody specific for gastric and gastroesophageal adenocarcinomas. Preclinically, claudiximab was shown to inhibit tumor growth and to kill cancer cells by indirect (complement-dependent cytoxicity, antibody-dependent cellular cytotoxicity) and direct mechanisms (antiproliferative and proapoptotic effects). The aim of this phase I study is to establish safety, toxicity and maximal tolerable dose of a single infusion of claudiximab in patients suffering from relapsing, advanced gastroesophageal and gastric adenocarcinoma
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Universitätsklinikum Essen, Innere Klinik (Tumorforschung), Essen, , Germany
Universität Heidelberg, Nationales Centrum fßr Tumorerkrankungen (NCT), Heidelberg, , Germany
Johannes Gutenberg Universität, 1.Med Klinik und Poliklinik, Mainz, , Germany
Klinikum Rechts-der-Isar, III.Medizinische Klinik und Poliklinik, MĂźnchen, , Germany
Piejuras Hospital, Liepaja, , Latvia
Pauls Stradins University, Riga, , Latvia
Contact Details
Name: Martin Schuler, Prof.Dr.med.
Affiliation: Innere Klinik (Tumorforschung) Universitätsklinikum Essen Hufelandstr. 55 45122 Essen, GERMANY
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
